news

iPSC-CAR-NK cell therapy exhibits autoimmune potential

2
SHARES

The genetically edited allogeneic product could serve as an immune-modulatory therapy for severe autoimmune diseases, data suggests.

iPSC-CAR-NK cell therapy

New clinical data has demonstrated the first application of iPSC-CAR-NK cells in autoimmune disease. The cell-based therapy successfully inducted immune reset in refractory systemic sclerosis (SSc), according to the study findings. 

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The patient received four doses of the off-the-shelf, dual-targeting cell product QN-139b (6 × 10⁸ cells per dose).

Following six months of treatment, results demonstrated:

  • significant reduction in autoantibodies and normalisation of complement levels
  • dramatic improvement in modified Rodnan skin score (mRSS)
  • enhanced ACR-CRISS score
  • histological evidence of B cell clearance, fibrosis suppression, lymphocyte depletion in affected tissues, and skin microvascular remodelling.

“We are proud to see a patient with nearly two decades of systemic sclerosis achieve such meaningful clinical improvement following QN-139b treatment”

“We are proud to see a patient with nearly two decades of systemic sclerosis achieve such meaningful clinical improvement following QN-139b treatment,” commented Dr Luhan Yang, Founder and CEO of Hangzhou Qihan Biotech Co., Ltd. “Our years of innovation in reducing allogeneic immune rejection now empower not only iPSC-NK but also iPSC-T and universal CAR-T platforms—offering renewed hope for patients with autoimmune diseases worldwide.”

About the iPSC-CAR-NK cell therapy

Qihan Biotech shared that the therapy utilises the company’s high-throughput gene editing platform to eliminate pathogenic B cells and plasma cells by targeting both CD19 and BCMA.

One of its safety features includes production from sequenced monoclonal iPSC lines to minimise genomic toxicity. Furthermore, QN-139b includes a tEGFR safety switch which serves to reduce risk of disease flares in those with autoimmune conditions. Its low-immunogenicity design also strengthens its in vivo expansion and therapeutic durability, stated Qihan Biotech.

Findings from the iPSC-CAR-NK cell therapy study were published in Cell.

Looking ahead at future of development of iPSC-NK therapies, “meaningful progress will depend on sustained investment in cell engineering, manufacturing process optimisation, analytical development and regulatory alignment”, wrote Stefan Braam, Co-Founder and Chief Technical Officer, Cellistic, in an EPR article earlier this month.

Share via
Share via